|
Match
|
Document |
Document Title |
|
|
7501486 |
Peptides that selectively home to heart vasculature and related conjugates and methods
The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has...
|
|
|
7501395 |
Method of screening for antianxiety drugs
An anxiolytic drug of the invention comprises an orexin receptor antagonist, a pharmacologically acceptable salt thereof, or a solvate thereof as an active ingredient. A method for screening a...
|
|
|
7501130 |
Methods for treating myofascial pain
A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount...
|
|
|
7501394 |
Compounds for targeting hepatocytes
We describe compounds that bind to and are internalized by hepatocytes. Association of these compounds to other molecules or complexes can be used to target the molecules or complexes to...
|
|
|
7501396 |
Methods for treating joint pain using poly-gamma-glutamic acid
Methods for treating joint pain such as temporomandibular joint disorders, osteoarthritis of the knee, hip and other types of inflammatory joint diseases. The methods involve the use of...
|
|
|
7501485 |
Bioactive keratin peptides
Compositions containing biologically active peptides are disclosed. Active peptides are isolated fragments derived from human hair or sheep wool keratin proteins. Compositions may be prepared for...
|
|
|
7498306 |
Peptides binding to the phosphatase 2A protein
The invention relates to novel synthetic or natural E4orf4 or Bcl-2 peptides particularly useful in antitumoral, antiviral and antiparasitic treatments, said peptides being less than 30 amino acids...
|
|
|
7498308 |
Method of treating a subject suffering stroke comprising administering Glucagon-like peptide-1 analogs
Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating...
|
|
|
7498303 |
GNRH analogues for treatment of urinary incontinence
The use of at least one GnRH analogue for the preparation of a medicament for the prevention and/or treatment of side effects of ovarectomy or symptoms associated with reproductive senescence in...
|
|
|
7498299 |
Procollagen (III) propeptides and related substances for treating fibrotic diseases
In a method of treating a fibrotic disease, a composition is administered to a mammal an effective amount, wherein the composition contains a polypeptide selected from the group consisting of rat,...
|
|
|
7498408 |
Ryanodine receptor polypeptides
The genes encoding ryanodine receptor homologs have been characterized from multiple insect families including lepidopteran tobacco budworm ( Heliothis virescens ), homopteran green peach aphid (...
|
|
|
7498304 |
Angiogenesis-modulating compositions and uses
Hedgehog agonists and antagonists can be used to regulate angiogenesis, and to prevent angiogenesis driven pathologies. Furthermore, hedgehog agonists and antagonists have utility in modulating...
|
|
|
7498307 |
Combinations of DnaK inhibitors with known antibacterial agents
Compositions, methods and kits are provided comprising (a) a therapeutically effective amount of a DnaK inhibitor; and (b) a therapeutically effective amount of a known antibacterial agent. Such...
|
|
|
7498305 |
Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that...
|
|
|
7495087 |
Cysteine muteins in the C-D loop of human interleukin-11
Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.
|
|
|
7494971 |
Pharmaceutical preparations and medicines capable of generating, and/or containing, thrombin
The invention relates to a pharmaceutical active ingredient preparation for producing a medicament that contains thrombin or has a thrombin-generating capacity and compositions comprising thereof....
|
|
|
7494977 |
Polypeptides homologous to VEGF and BMP1
The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor...
|
|
|
7494976 |
Caveolin peptides and their use as therapeutics
The present invention relates generally to compositions and methods useful for treating various conditions and afflictions, such as inflammation and cancer. More specifically, the present invention...
|
|
|
7494984 |
Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
The invention encompasses a series of bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the...
|
|
|
7491796 |
Retro-inversion peptides that target GIT receptors and related methods
Retro-inverted forms of GIT targeting agents that target specific receptor sites in vivo and/or promote uptake of active agents and/or enhance active agent delivery across the GIT into the systemic...
|
|
|
7491701 |
Peptides that bind to HSP90 proteins
YSLPGYMVKKLLGA (SEQ ID NO:1) and its active analogs, compositions, and methods of use.
|
|
|
7491698 |
Mixing and matching TC proteins for pest control
The subject invention relates to the surprising discovery that toxin complex (TC) proteins, obtainable from Xenorhabdus, Photorhabdus, and Paenibacillus, can be used interchangeably with each...
|
|
|
7491403 |
Pharmaceutical botulinum toxin compositions
Botulinum toxin, a well know systemic poison, produces favorable therapeutic effect by virtue of regionally attaching to nerves within the myoneural junction and possibly other tissues in a target...
|
|
|
7491699 |
Peptide nanostructures and methods of generating and using the same
A tubular or spherical nanostructure composed of a plurality of peptides, wherein each of the plurality of peptides includes no more than 4 amino acids and whereas at least one of the 4 amino acids...
|
|
|
7491696 |
Proteolysis resistant active VEGF
The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino...
|
|
|
7491697 |
Muteins of fibroblast growth factor 21
The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are...
|
|
|
7488316 |
Control of drug release by transient modification of local microenvironments
Methods, formulations, and devices are provided for enhancing drug delivery from a medical device. The method is provided for increasing the rate or quantity of a drug formulation released from an...
|
|
|
7488713 |
Cancer treatment using C-type natriuretic peptides
The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i.e., the...
|
|
|
7488716 |
Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2...
|
|
|
7488710 |
SFRP and peptide motifs that interact with SFRP and methods of their use
This disclosure relates to a peptide motif and proteins containing the motif that are capable of binding to secreted Frizzled-related protein family members. Accordingly, the disclosure also...
|
|
|
7485617 |
Osteoinductive materials
The present invention concerns improved osteoinductive materials comprising matrix materials and morphogenetic roteins, wherein depending on the subject matter the proteins may be dimeric or...
|
|
|
7485621 |
Tumor tag and the use thereof
The invention provides a new tumor tag, RL5 protein, the polynucleotide encoding RL5 protein, and the method of producing RL5 protein by recombinant technology. The invention also discloses the use...
|
|
|
7485713 |
Polypeptides comprising growth hormone receptor extracellular domain and glycosylphosphatidylinositol
The present invention relates to polypeptides which comprise a receptor binding domain of a cytokine and a domain which includes a signal sequence for the attachment of glycosylphosphatidylinositol...
|
|
|
7485624 |
Method for treating cardiac muscle disorders
Methods for treating cardiac muscle disorders, such as cardiac arrhythmias, by administration of a neurotoxin to cardiac muscle are disclosed. Bradycardia can be alleviated for several months by a...
|
|
|
7485623 |
Reduction of breast density with 4-hydroxy tamoxifen
A method of treatment comprises administering 4-hydroxy tamoxifen percutaneously to a patient having dense breast tissue. The 4-hydroxy tamoxifen may be formulated in a hydroalcoholic gel or an...
|
|
|
7485304 |
Non-toxic mucosal adjuvant
A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic...
|
|
|
7485620 |
Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
The present invention relates to compositions containing unacylated ghrelin and derivatives thereof and their uses in the control of glycemia in ageing patients, GH deficient patients, diabetic...
|
|
|
7485616 |
Methods of investigating, diagnosing, and treating amyloidosis
The present invention provides a therapeutic method for removing amyloid fibrils from a patient. The present invention also provides a transgenic animal that develops systemic AA amyloidosis within...
|
|
|
7485622 |
Paralytic peptide for use in neuromuscular therapy
The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This...
|
|
|
7482326 |
Endothelial-monocyte activating polypeptide III
A human EMAP III polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing...
|
|
|
7482323 |
Intracellular interleukin-1 receptor antagonist and uses thereof
Matrix metalloproteinases are major mediators of tissue destruction in various chronic inflammatory disorders. The present invention demonstrates that over-expression of intracellular isoform of...
|
|
|
7482433 |
Peptides and compounds that bind to the IL-5 receptor
Interleukin-5 receptor (IL-5R) ligands comprising amino sequences of formula TGGGDGYVX 3 VEX 4 ARCPTCK, EGYVX 3 VEX 4 ARCPTCK, EGYVX 3 VEX 4 ARCPTCR, GYVX 3 VEX 4 ARCPTCG, EGYVX 3 VEX 4 ARCPTCG,...
|
|
|
7482320 |
Modulation of smooth muscle cell proliferation
There is provided a novel use for vascular endothelial growth factor, herein designated VEGF-X, and a CUB domain present in the sequence of VEGF-X, which enhance smooth muscle cell proliferation...
|
|
|
7482322 |
Plexin family-like polypeptide, and uses thereof
The present invention is directed to a novel plexin family like DNA, a gene containing the DNA, novel polypeptide encoded by the DNA, a recombinant protein containing the polypeptide or...
|
|
|
7482130 |
NP95: methods of assaying for cell cycle modulators
The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding NP95, which is involved in modulation of cell...
|
|
|
7482321 |
Extended glucagon-like peptide-1 analogs
The invention encompasses GLP-1 peptides with modifications at various positions coupled with an extended C-terminus that provides increased stability.
|
|
|
7482008 |
Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several...
|
|
|
7482327 |
Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules
The present invention provides use of soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig in the treatment of...
|
|
|
7482325 |
Downregulation of immune response by administering B7RP-2 fusion protein
The present invention provides B7 Related Protein-2 (B7RP-2) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells,...
|
|
|
7482427 |
Positive modulator of bone morphogenic protein-2
Compounds of the present invention of formula I and formula II are disclosed in the specification and wherein the compounds are modulators of Bone Morphogenic Protein activity. Compounds are...
|